Should You Buy Novavax Before Its U.S. Regulatory Filing?

Novavax (NASDAQ: NVAX) shares have gained about 50% so far this year. That may sound impressive. But the shares have actually dropped 46% from a high reached earlier in the year. The reason for such a move? Investors frowned as Novavax delayed the submission of its coronavirus vaccine candidate to regulators more than once.

Now, it looks like things are back on track for the biotech company. Novavax has applied for authorization or approval in seven countries and the EU. And the company aims to complete its Emergency Use Authorization submission in the U.S. by the end of the year. Investors have viewed an authorization in the U.S. as the major prize for this biotech company. And that means an upcoming filing and potential authorization could be two major catalysts. So now the question is: Should you buy Novavax shares before its big regulatory filing? Let's find out.

Image source: Getty Images.

Continue reading

Source Fool.com